Navigation Links
Van Andel Research Institute finding could lead to reduced side effects in anti-cancer antibiotics
Date:6/28/2011

Grand Rapids, Mich. (June 28, 2011) Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

One particularly promising anti-cancer antibiotic is Geldanamycin and a modified form of this drug known as 17AAG. Despite its proven ability to selectively kill many different forms of cancer in laboratory studies, the use of these drugs is limited due to side effects, mainly liver failure, in patients.

Newly published results from Van Andel Research Institute (VARI) researchers have determined how the anti-cancer antibiotic Geldanamycin and its derivative 17AAG work in more detail and have uncovered a possible explanation for side effects observed in clinical trials of the drug.

"The article provides novel and significant information about the clinical potential of these compounds in cancer therapy," said Yale School of Medicine Professor and Chair of Pharmacology Joseph Schlessinger, Ph.D.

Although there was much preclinical interest in the antibiotic Geldanamycin as an anti-cancer drug, it turned out to be a poor candidate for clinical trials because of its toxicity. Derivatives such as 17AAG were developed to decrease toxicity and are still being evaluated in clinical trials.

VARI researchers determined how Geldanamycin and 17AAG work in more detail in a study published in Proceedings of the National Academy of Sciences U.S.A., which could inform future drug design, and also found a way to potentially decrease the antibiotics' toxicity.

"There was so much interest early on in Geldanamycin because it resulted in the degradation of oncoproteins, important protein targets in tumor cells," said VARI Research Scientist and lead author of the paper Qian Xie, M.D., Ph.D.

"If there is a chance of decreasing the toxicity of Geldanamycin and 17AAG, it would be a boon in the treatment of cancer," said George Vande Woude, Ph.D., head of the Laboratory of Molecular Oncology at VARI that published the study.


'/>"/>

Contact: Joe Gavan
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related medicine news :

1. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
2. Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade
3. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
4. Religion benefits traumatic brain injury victims, Wayne State University research finds
5. Leading research organizations announce top-tier journal for biomedical and life sciences
6. New Crops for the Future Research Centre -- for food and non-food uses
7. Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report
8. UH Cancer Center receives $3.58 million gift for mesothelioma research
9. New application for iPhone may support monitoring and research on Parkinsons disease
10. TGen, Tecan and ASU Biodesign Institute develop sample preparation solution for proteomic research
11. Researchers identify components of speech recognition pathway in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology: